CJC-1295 no DAC

🔬What Is CJC-1295 no DAC

CJC-1295 without DAC, also known as Modified GRF (1-29), is a truncated synthetic analog of growth hormone-releasing hormone comprising the first 29 amino acids of native GHRH with four amino acid substitutions to resist enzymatic degradation. Unlike the DAC variant, it has a shorter half-life of approximately 30 minutes, producing pulsatile GH release that more closely mimics the body's natural secretory pattern. It acts by binding to the GHRH receptor on somatotroph cells in the anterior pituitary, stimulating the synthesis and secretion of growth hormone. This pulsatile profile is particularly valued in research examining physiological GH dynamics and synergistic effects when combined with GH secretagogues such as Ipamorelin or GHRP-2.

📊Clinical Studies & Results

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic GHRH analogue with enhanced enzymatic stability:

• ▪Demonstrated robust, pulsatile GH release that closely mimics the body's natural GH secretion pattern, preserving the physiological GH pulse-trough cycle
• ▪Combined administration with GHRP peptides produced synergistic GH release 3-10x greater than either peptide alone, establishing CJC/GHRP as the gold standard GH axis protocol
• ▪Stimulated GH release through the GHRH receptor (GHRHR) on pituitary somatotrophs, complementing rather than competing with ghrelin-pathway secretagogues
• ▪Maintained pulsatile GH release without desensitization over 12-week administration protocols in clinical settings
• ▪Increased IGF-1 levels by 30-60% from baseline while preserving normal feedback regulation, unlike exogenous GH administration
• ▪Enhanced slow-wave sleep-associated GH pulses, improving both sleep quality and nighttime recovery processes

CJC-1295 (no DAC) is the preferred GHRH analogue for pulsatile GH optimization, providing the signaling half of the GH axis while preserving natural feedback regulation and sleep architecture.

🏆Benefits

• Pulsatile GH Release – Preserves natural GH pulse-trough pattern unlike continuous GH elevation
• Powerful Synergy with GHRPs – 3-10x amplified GH output when stacked with Ipamorelin or GHRP-2
• Increases IGF-1 30-60% – Meaningful elevation while maintaining physiological feedback control
• No Desensitization – Maintains efficacy over extended 12+ week protocols
• Enhances Sleep Quality – Amplifies slow-wave sleep GH pulses for overnight recovery
• Preserves Natural Feedback – Works with the body's GH axis rather than overriding it

⚠️Possible Side Effects

• ▪Generally well-tolerated – the shorter half-life produces pulsatile GH release that more closely mimics natural physiology, resulting in fewer sustained side effects compared to the DAC variant
• ▪Transient flushing, warmth, or tingling at the injection site shortly after administration – typically mild and brief
• ▪Mild headache or dizziness reported in some research protocols, usually resolving quickly
• ▪Transient changes in glucose metabolism are possible but less pronounced than with sustained-release GH analogs – monitoring is still considered prudent at higher research doses
• ▪Mild water retention may occur during initial administration periods

🎯Ideal For

• →Growth hormone axis optimization research
• →Anti-aging and body composition improvement protocols
• →Synergistic stacking with Ipamorelin or GHRP-2/6 for maximum GH output
• →Sleep quality enhancement and nighttime recovery optimization
• →Athletes and active individuals seeking natural GH elevation
• →IGF-1 optimization without exogenous growth hormone